Tirzepatide: Scientific Profile

Publicado el 28 de diciembre de 2025 · Actualizado el 20 de septiembre de 2026

Tirzepatide (LY3298176), CAS 2023788-19-2: synthetic 39-amino-acid peptide, the first dual agonist of the GIP/GLP-1 receptors. Reagent for in vitro and preclinical research (RUO).

Tirzepatide (English name Tirzepatide; development code LY3298176; CAS 2023788-19-2) is a long-acting synthetic peptide belonging to the class of dual incretin agonists, commonly called "twincretins". With molecular formula C225H348N48O68 and an approximate molecular weight of 4813.5 g/mol, it is a 39-amino-acid chain structurally derived from the backbone of glucose-dependent insulinotropic polypeptide (GIP), to which a C20 diacid fatty-acid modification has been added via a linker. This acylation gives it reversible binding to serum albumin, which markedly prolongs its half-life in research models —on the order of five days— and has made it possible to explore weekly dosing schedules. Tirzepatide was developed by Eli Lilly and is one of the molecules that has driven the recent interest in dual-mechanism metabolic pharmacology.

From a structural standpoint, Tirzepatide is a long-chain peptide analog designed to simultaneously activate two class B G protein-coupled receptors: the GIP receptor (GIPR) and the glucagon-like peptide-1 receptor (GLP-1R). The design of this type of unimolecular agonist seeks to bring together in a single sequence the recognition determinants of both incretin systems, with a relative potency biased toward the GIPR. The attached lipid chain, a resource also used in other long-acting incretin analogs, is the element that explains the plasma stability observed in preclinical and clinical research models.

The proposed mechanism of action is based on the dual, coordinated activation of both incretin pathways. Through the GLP-1R arm, the molecule reproduces classic incretin signaling: in preclinical models, potentiation of glucose-dependent insulin secretion, slowing of gastric emptying, and modulation of hypothalamic circuits linked to satiety have been described. Through the GIPR arm, activation of the GIP receptor is associated in experimental models with complementary effects on lipid metabolism in adipose tissue and on insulin sensitivity, as well as a possible potentiation of the incretin response itself. The working hypothesis underlying this class is that balanced co-activation of GIPR and GLP-1R produces an integrated metabolic effect superior to that of GLP-1 agonism alone.

In the research setting, Tirzepatide is used as a reference tool for studying dual incretin signaling, glucose homeostasis, appetite regulation, and energy metabolism in cell and animal models. Its long-acting profile makes it useful for designing experimental protocols with spaced dosing and for comparing the relative contribution of the GIP and GLP-1 pathways against selective agonists. It is also a common comparator in the development of new incretin co-agonists and tri-agonists.

Tirzepatide is supplied as a lyophilized powder for reconstitution. Its handling in the laboratory follows the usual good practices for long-chain peptides: frozen storage of the lyophilized vial, protection from light and reconstitution with bacteriostatic water or the sterile diluent indicated in the protocol, avoiding vigorous agitation that could denature the chain. This product is offered exclusively as a research reagent (research use only): it is not intended for the diagnosis, prevention or treatment of any disease, nor for human or veterinary consumption.

Mechanism of action

Tirzepatide simultaneously activates two Gs protein-coupled receptors of the secretin family: GIPR and GLP-1R. Activation of GLP-1R in pancreatic β cells potentiates glucose-dependent insulin secretion via elevation of cAMP, phosphorylation of PKA and EPAC2, with consequent activation of KATP channels and exocytosis of insulin granules. In parallel it suppresses glucagon secretion by α cells and slows gastric emptying, attenuating the postprandial glucose excursion. Activation of GIPR in adipocytes increases insulin sensitivity, promotes free fatty acid uptake and modulates lipogenesis via AKT/mTOR signaling. In the central nervous system, Tirzepatide crosses circumventricular areas (area postrema, arcuate nucleus) and activates POMC/CART neurons and inhibits AgRP/NPY neurons, producing sustained satiety. In vivo studies demonstrate a 15-22% reduction in body weight in DIO murine models. Half-life: 116.7 hours. Subcutaneous bioavailability: 80%. Elimination: proteolytic catabolism, with no significant renal/hepatic excretion. Affinity for GIPR is comparable to native GIP, while affinity for GLP-1R is ~5x lower than endogenous GLP-1, which avoids receptor desensitization.

Mechanism summary

Dual agonist GIPR/GLP-1R of 39 amino acids with a half-life of ~5 days that enhances glucose-dependent insulin secretion, suppresses glucagon and modulates hypothalamic satiety circuits; its C20 side chain via γGlu-2xOEG confers binding to albumin.

Clinical Studies (8)

Tirzepatide versus Semaglutide for Weight Management (Frias JP, et al. · New England Journal of Medicine · 2025) — Head-to-head comparison showing superiority of tirzepatide over semaglutide for weight loss. PMID 40353578.
SYNERGY-NASH: Tirzepatide in MASH with fibrosis (Loomba R, Hartman ML, Lawitz EJ, et al. · New England Journal of Medicine · 2024) — 52-week phase 2 study in 190 patients with biopsy-confirmed MASH F2/F3, evaluating tirzepatide vs placebo. PMID 38856224.
Tirzepatide Once Weekly for the Treatment of Obesity (Jastreboff AM, et al. · New England Journal of Medicine · 2022) — Phase 3 SURMOUNT-1 clinical trial with 2,539 participants showing significant weight loss. PMID 35658024.
SURPASS-2: Tirzepatide vs Semaglutide 1 mg weekly in T2DM (Frías JP, Davies MJ, Rosenstock J, et al. · New England Journal of Medicine · 2021) — 40-week phase 3 head-to-head trial in 1,879 patients with T2DM inadequately controlled with metformin, comparing tirzepatide 5/10/15 mg vs semaglutide 1 mg weekly. PMID 34170647.
Discovery and molecular characterization of tirzepatide (Coskun T, Sloop KW, Loghin C, et al. · Molecular Metabolism · 2018) — Preclinical characterization of the first dual GIP/GLP-1 agonist, including receptor affinity, pharmacokinetics, and efficacy in rodent and non-human primate models. PMID 30473097.
Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1): a double-blind, randomised, phase 3 trial (Rosenstock, et al. · The Lancet · 2021) PMID 34186022.
Dual GIP and GLP-1 Receptor Agonist Tirzepatide Improves Beta-cell Function and Insulin Sensitivity in Type 2 Diabetes (Thomas, et al. · Journal of Clinical Endocrinology & Metabolism · 2021) PMID 33236115.
Tirzepatide, a dual GIP/GLP-1 receptor co-agonist for the treatment of type 2 diabetes with unmatched effectiveness regrading glycaemic control and body weight reduction (Nauck, D'Alessio · Cardiovascular Diabetology · 2022) PMID 36050763.

Warnings

Tirzepatide is a research-use-only (RUO) compound; the following warnings and handling considerations apply to its laboratory use:

Theoretical risk of thyroid tumors in rodent studies
Possible acute pancreatitis
Hypoglycemia with co-administration of insulin/sulfonylureas
Delays absorption of oral medications
Possible worsening of diabetic retinopathy
Hypersensitivity reactions including anaphylaxis
Do not use during pregnancy (category not assigned, fetal risk in animals)
Personal/family history of medullary thyroid carcinoma
Multiple endocrine neoplasia type 2 (MEN2)
Hypersensitivity to tirzepatide
Active acute pancreatitis

Technical data

CAS: 2023788-19-2
Molecular formula: C225H348N48O68
Molecular weight: 4813.45 Da
Compound type: peptide
Storage: -20 °C liofilizado; 2-8 °C reconstituido
Shelf life (lyophilized): 36 months at 2-8°C
Shelf life (reconstituted): 21-28 days at 2-8°C with bacteriostatic preservative
Light-sensitive: Sí

Available for research

Tirzepatide is available as a research reagent (RUO) with HPLC-verified purity and COA per batch:

Tirzepatide

Frequently asked questions about Tirzepatide

What is Tirzepatide?

Tirzepatide (LY3298176), CAS 2023788-19-2: synthetic 39-amino-acid peptide, the first dual agonist of the GIP/GLP-1 receptors. Reagent for in vitro and preclinical research (RUO).

What is the mechanism of action of Tirzepatide?

What is Tirzepatide researched for?

In preclinical research, Tirzepatide is studied mainly in: research on glycemic homeostasis; models of weight reduction; studies of insulin sensitivity. Material exclusively for scientific research.

What are the chemical properties of Tirzepatide?

Molecular formula C225H348N48O68; molecular weight 4813.45 Da; CAS number 2023788-19-2.

How is Tirzepatide stored?

Condiciones de conservación: -20 °C liofilizado; 2-8 °C reconstituido; estabilidad liofilizado: 36 meses a 2-8°C; una vez reconstituido: 21-28 días a 2-8°C con conservante bacteriostático; protéjase de la luz.

What routes of administration are studied for Tirzepatide?

In the research models the following are described: Subcutaneous. Use is exclusively for scientific research.